MedTrace Logo

A Study to Learn About Recifercept in Patients With Achondroplasia

NCT05659719 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 248

Last updated 2024-09-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn about the study medicine (called recifercept) in people with achondroplasia. Achondroplasia is a very rare disease and patients of achondroplasia have short arms and legs. The study will include data already collected from a recifercept clinical trial and data collected from a separate study of achondroplasia. This study will compare patient experiences and will help the investigators determine if the study medicine, recifercept, is effective.

Conditions

Interventions

OTHER

Recifercept

Patients received recifercept intervention in the phase 2 clinical trial

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
3 Months
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-19
Primary Completion
2023-05-16
Completion
2023-05-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05659719 on ClinicalTrials.gov